March 1, 2017
FOR IMMEDIATE RELEASE
Contact: Jeff Golini, Executive Scientist
Kre-Alkalyn® Buffered Creatine Awarded Third International Patent
Billings, MT. – Nutritional supplement manufacturer All American Pharmaceutical and Executive Scientist Dr. Jeff Golini, are proud to announce they have received yet another patent for their flagship ingredient Kre-Alkalyn®, the world’s only fully stable and buffered creatine monohydrate.
Two previous international patents were granted from Australia and New Zealand. This third international patent has been awarded by Canada (#2,488,463). To date, 31 additional patents are pending worldwide. In the U.S., Kre-Alkalyn® is protected under patent #6,399,611.
According to Dr. Golini, “Kre-Alkalyn represent a major breakthrough in performance supplementation thanks to what we call ‘pH-Correct’ creatine stabilization technology. I discovered that “buffering” creatine to pH-12 produced a stable molecule in fluids. Kre-Alkalyn is the only creatine monohydrate product with a pH of 12 because its molecules are synthesized with ‘buffering’ agents using our multi-patented manufacturing process.”
In addition to its patents, four Kre-Alkalyn® research articles, authored by Dr. Golini, have appeared in various respected peer-reviewed journals. The compound is available in numerous sports and fitness products sold worldwide.